Geographic Atrophy clinical trials at UC Davis
1 research study open to eligible people
Metformin vs. no treatment in the progression of geographic atrophy (GA), a type of age-related macular eye degeneration (AMD)
“Can Metformin, used to treat Diabetes, slow the progression of geographic atrophy in patients with age-related macular eye degeneration?”
open to eligible people ages 55 years and up
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Davis, California and other locations